ZA9610741B - 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists - Google Patents

4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Info

Publication number
ZA9610741B
ZA9610741B ZA9610741A ZA9610741A ZA9610741B ZA 9610741 B ZA9610741 B ZA 9610741B ZA 9610741 A ZA9610741 A ZA 9610741A ZA 9610741 A ZA9610741 A ZA 9610741A ZA 9610741 B ZA9610741 B ZA 9610741B
Authority
ZA
South Africa
Prior art keywords
substituted piperidine
pct
piperidine analogs
analogs
sec
Prior art date
Application number
ZA9610741A
Other languages
English (en)
Inventor
Christopher F Bigge
Eckard Weber
Nancy C Lan
Zhang-Lin Zhou
Sui Xiong Cai
Richard Woodward
John F W Keana
Jonathan Wright
Original Assignee
Warner Lambert Co
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Cocensys Inc filed Critical Warner Lambert Co
Publication of ZA9610741B publication Critical patent/ZA9610741B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
ZA9610741A 1995-12-22 1996-12-19 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists ZA9610741B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US919295P 1995-12-22 1995-12-22

Publications (1)

Publication Number Publication Date
ZA9610741B true ZA9610741B (en) 1997-06-24

Family

ID=21736135

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610741A ZA9610741B (en) 1995-12-22 1996-12-19 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Country Status (22)

Country Link
US (4) US6130234A (no)
EP (1) EP0869791B1 (no)
JP (1) JP2000502352A (no)
AT (1) ATE239473T1 (no)
AU (1) AU719430B2 (no)
BG (1) BG63424B1 (no)
BR (1) BR9612153A (no)
CA (1) CA2240038A1 (no)
CZ (1) CZ177898A3 (no)
DE (1) DE69628035T2 (no)
DK (1) DK0869791T3 (no)
EA (1) EA001133B1 (no)
ES (1) ES2196196T3 (no)
IL (1) IL125060A (no)
MX (1) MX9805032A (no)
NO (1) NO312028B1 (no)
NZ (1) NZ325735A (no)
PL (1) PL327413A1 (no)
PT (1) PT869791E (no)
SK (1) SK82398A3 (no)
WO (1) WO1997023214A1 (no)
ZA (1) ZA9610741B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
AU4424697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
GB9704948D0 (en) * 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
BR9814867A (pt) 1997-10-24 2000-10-03 Warner Lambert Co Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
WO2002014867A2 (en) * 2000-08-11 2002-02-21 Agilix Corporation Ultra-sensitive detection systems
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
US6642256B2 (en) 2000-12-21 2003-11-04 Warner-Lambert Company Llc Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
SI1409477T1 (sl) 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
EP1420644B1 (de) * 2001-08-23 2006-05-31 Bayer CropScience S.A. Substituierte propargylamine
WO2003035641A1 (fr) * 2001-10-22 2003-05-01 Shionogi & Co., Ltd. Nouveau derive carbamoyl-pyrrolidone
WO2003056298A2 (en) * 2001-11-06 2003-07-10 Agilix Corporation Sensitive coded detection systems
DE10201550A1 (de) * 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy-Piperidine
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
JP2008529035A (ja) * 2005-02-03 2008-07-31 パーキンエルマー エルエーエス，インク． 多次元シグナルを用いる超高感度検出システム
ES2389500T3 (es) 2005-03-31 2012-10-26 Asahi Glass Company, Limited Agente protector para una célula neuronal retiniana que contiene un derivado de prostaglandina F2 alfa como ingrediente activo
CA2604956A1 (en) * 2005-04-13 2006-10-26 Ube Industries, Ltd. Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
AU2006274245B2 (en) 2005-07-26 2011-11-24 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
BRPI0614063A2 (pt) 2005-07-26 2011-03-09 Sanofi Aventis derivados de cicloexilamina isoquinolona
WO2007047447A2 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
JP5318779B2 (ja) 2006-12-27 2013-10-16 サノフイ シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8524737B2 (en) 2008-06-24 2013-09-03 Sanofi Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
KR101607090B1 (ko) 2008-06-24 2016-03-29 사노피 6-치환된 이소퀴놀린 및 이소퀴놀리논
ES2541827T3 (es) 2008-06-24 2015-07-27 Sanofi Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2705024B1 (en) * 2011-05-03 2015-12-16 Merck Sharp & Dohme Corp. Alkyne benzotriazole derivatives
CN103974698A (zh) 2011-11-22 2014-08-06 加利福尼亚大学董事会 用于治疗缺血性损伤的半胱胺和/或胱胺
US20160327543A1 (en) * 2014-01-02 2016-11-10 John P. Jasper Method for continuously monitoring chemical or biological processes
WO2017041095A1 (en) * 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
SI25272A (sl) * 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN114409680B (zh) 2018-01-19 2023-11-21 上海怡立舍生物技术有限公司 Ppar激动剂及其应用
WO2022251280A1 (en) * 2021-05-25 2022-12-01 Vividion Therapeutics, Inc. Compounds selective for jak1 and methods of use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA696999A (en) 1964-11-03 Ayerst, Mckenna And Harrison Therapeutic compounds and their preparation
US3255196A (en) 1966-06-07 Phenoxyalkyl piperidine derivatives
GB1052302A (no) * 1963-04-22
GB1055548A (en) 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
US3632767A (en) 1968-02-12 1972-01-04 Mallinckrodt Chemical Works Treatment of depression with 4-substituted piperidines
US3686187A (en) * 1970-05-25 1972-08-22 Abbott Lab 4-anilino-1-(4-p-fluorophenyl-1-butyl) piperidine compounds
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
DE2651574A1 (de) 1976-11-12 1978-05-18 Boehringer Mannheim Gmbh Ein neues aminopropanol-derivat und verfahren zu dessen herstellung
US4312876A (en) * 1979-02-23 1982-01-26 Hoechst-Roussel Pharmaceuticals Incorporated Antidepressive and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
GB2056435A (en) * 1979-06-26 1981-03-18 Ciba Geigy Ag Novel Tetrahydropyridine and Piperidine Substituted Benzofuranes and Related Compounds
DE2939292A1 (de) 1979-09-28 1981-04-09 Boehringer Mannheim Gmbh, 6800 Mannheim N-phenoxyalkylpiperidin-derivate, verfahrenn zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3421641A1 (de) * 1984-06-09 1985-12-12 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
JPS61115068A (ja) 1984-11-08 1986-06-02 Hokuriku Seiyaku Co Ltd ４−ベンジルピペリジニルプロポキシアニリン誘導体
US4567186A (en) * 1985-01-14 1986-01-28 Sterling Drug Inc. 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor
JPH0615529B2 (ja) 1985-04-01 1994-03-02 エーザイ株式会社 新規ピペリジン誘導体
EP0228893A3 (en) 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
DK623586A (da) 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
DE3703435A1 (de) 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
FR2620704B1 (fr) 1987-09-17 1991-04-26 Sanofi Sa Derives de (benzyl-4 piperidino)-1 propanol-2, leur preparation, leur utilisation comme antimicrobiens et les produits les contenant
DE3852551T2 (de) 1987-12-11 1995-05-18 Mitsui Petrochemical Ind Amine und deren verwendung.
ZA891901B (en) 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
FR2640266B2 (fr) 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5011834A (en) 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
EP0398578B1 (en) 1989-05-17 1997-03-12 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
US5149817A (en) 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
US5116846A (en) 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
US5169855A (en) 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
EP0554247B1 (en) 1990-05-10 2000-04-26 Pfizer Inc. Neuroprotective indolone and related derivatives
JPH04217945A (ja) 1990-07-18 1992-08-07 Zeria Pharmaceut Co Ltd 置換アルキルベンゼン誘導体およびそれを含有する抗潰瘍剤
MX9100513A (es) 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
FR2668149B1 (fr) 1990-10-18 1994-09-23 Synthelabo Le 1-(3,4-dihydro-2-oxo-1h-quinolein-6-yl)-2-[4-(2-phenyl-ethyl)piperidin-1-yl]ethanol, sa preparation et son application en therapeutique.
US5270312A (en) * 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
US5273977A (en) 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
JPH04312572A (ja) 1991-04-12 1992-11-04 Takeda Chem Ind Ltd 環状アミン化合物
US5231099A (en) 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
JPH06509069A (ja) 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
EP0524846A1 (fr) 1991-06-27 1993-01-27 Synthelabo Dérivés de 2-(pipéridin-1-y1) éthanol, leur préparation et leur application en thérapeutique
PL169884B1 (pl) 1991-07-17 1996-09-30 Pfizer Sposób wytwarzania nowych pochodnych 2-(4-hydroksypiperydyno)-1-alkanolowych PL PL PL
FR2681319B1 (fr) 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
HU211019B (en) 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
AU3364493A (en) 1992-01-28 1993-09-01 Smithkline Beecham Plc Compounds as calcium channel antagonists
US5202346A (en) 1992-02-25 1993-04-13 American Home Products Corporation Piperidinyl and piperazinyl derivatives
ES2060547B1 (es) 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
WO1994010166A1 (en) 1992-10-30 1994-05-11 Pfizer Inc. Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1994018172A1 (en) 1993-02-01 1994-08-18 Yoshitomi Pharmaceutical Industries, Ltd. Imidazolylbenzene compound and use thereof as medicine
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
TW281670B (no) 1993-09-02 1996-07-21 Hoffmann La Roche
CN1525171A (zh) * 1993-10-01 2004-09-01 ŦԼ�и��ױ��Ǵ�ѧ���� 用标示物编码的多元组合化学库
DE4335718A1 (de) 1993-10-20 1995-04-27 Merck Patent Gmbh Cyclische Aminderivate
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof

Also Published As

Publication number Publication date
CZ177898A3 (cs) 1998-12-16
SK82398A3 (en) 1999-03-12
JP2000502352A (ja) 2000-02-29
CA2240038A1 (en) 1997-07-03
NO982869D0 (no) 1998-06-19
NO312028B1 (no) 2002-03-04
PT869791E (pt) 2003-08-29
US20030105133A1 (en) 2003-06-05
AU719430B2 (en) 2000-05-11
DK0869791T3 (da) 2003-06-10
IL125060A (en) 2003-07-31
BG102561A (en) 1999-04-30
NO982869L (no) 1998-08-24
ATE239473T1 (de) 2003-05-15
DE69628035T2 (de) 2004-02-12
NZ325735A (en) 2000-02-28
EA199800591A1 (ru) 1999-02-25
US6130234A (en) 2000-10-10
BG63424B1 (bg) 2002-01-31
MX9805032A (es) 1998-11-30
EP0869791A1 (en) 1998-10-14
IL125060A0 (en) 1999-01-26
WO1997023214A1 (en) 1997-07-03
DE69628035D1 (de) 2003-06-12
US6448270B1 (en) 2002-09-10
EP0869791A4 (en) 1999-04-28
BR9612153A (pt) 1999-12-28
US20030100018A1 (en) 2003-05-29
EP0869791B1 (en) 2003-05-07
PL327413A1 (en) 1998-12-07
EA001133B1 (ru) 2000-10-30
ES2196196T3 (es) 2003-12-16
AU1431097A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
ZA9610741B (en) 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
IL125061A0 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
PL328816A1 (en) Novel substituted cyclic amino acids as pharmaceutic agents
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1622914A4 (en) NOVEL COMPOUNDS OF PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE
FI964340A (fi) Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina
GR3033528T3 (en) Novel piperidine derivatives with paf antagonist activity
DE69803458T2 (de) Tricyclisch substituierte 2,4-Dithi(oxo)-pyrimidin-5-yl-Verbindungen als P2- Purinoceptor-Antagonisten
PA8535901A1 (es) Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato
GR3034354T3 (en) IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components